We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 15 for:    Chimerix

Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

Expanded access is currently available for this treatment.
Verified October 2017 by Chimerix
Sponsor:
ClinicalTrials.gov Identifier:
NCT02596997
First Posted: November 4, 2015
Last Update Posted: October 10, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Chimerix
  Purpose
Provide patients with serious AdV infection or disease access to treatment with BCV.

Condition Intervention
Adenovirus Drug: Brincidofovir

Study Type: Expanded Access     What is Expanded Access?
Official Title: An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

Further study details as provided by Chimerix:

Intervention Details:
    Drug: Brincidofovir
    Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week
    Other Name: BCV CMX001
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Months and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Confirmed serious AdV infection based on clinical symptoms and laboratory testing showing AdV in the blood or other bodily fluids
  • Able to swallow medication, either tablet or liquid

Exclusion Criteria:

  • Previous dosing with Brincidofovir
  • If female, not pregnant or trying to become pregnant
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02596997


Contacts
Contact: Garrett Nichols, MD 919-287-6006 gnichols@chimerix.com

  Show 45 Study Locations
Sponsors and Collaborators
Chimerix
  More Information

Responsible Party: Chimerix
ClinicalTrials.gov Identifier: NCT02596997     History of Changes
Other Study ID Numbers: CMX001-351
First Submitted: November 3, 2015
First Posted: November 4, 2015
Last Update Posted: October 10, 2017
Last Verified: October 2017

Keywords provided by Chimerix:
Adenovirus Brincidofovir

Additional relevant MeSH terms:
Adenoviridae Infections
DNA Virus Infections
Virus Diseases